According to FutureWise analysis the market for intravitreal (ivt) injectables in 2023 was US$ 15.7 billion, and is expected to reach US$ 27 billion by 2031 at a CAGR of 6.5%.
Intravitreal injection is a medical procedure involving the administration of drugs directly into the eyeball through a fine needle. This technique allows medications to be delivered to the vitreous humor, the gel-like substance within the eye, which is effective in treating various eye conditions. These conditions include age-related macular degeneration (AMD), diabetic retinopathy, and intraocular infections such as endophthalmitis.
Compared to topical treatments, intravitreal injections provide a more targeted approach to medication delivery. The needle can bypass several anatomical barriers like the cornea, conjunctiva, and lens, as well as dynamic barriers such as tears and aqueous humor. Additionally, this method can potentially minimize adverse effects on other body tissues, a concern that may arise with systemic intravenous medication delivery.
Wet age-related macular degeneration (AMD) is characterized by vision loss due to the growth of abnormal, leaky blood vessels that infiltrate the retina, leading to fluid accumulation and retinal swelling. A key factor in this process is a molecule called vascular endothelial growth factor (VEGF), which stimulates the development of these blood vessels. Over the past 15 years, numerous medications aimed at inhibiting VEGF activity have been developed. These anti-VEGF treatments have proven effective in reducing swelling, partially restoring vision, or stabilizing disease progression.
Due to their large molecular structure, anti-VEGF medications must be delivered via injection into the eye, as they cannot be taken orally or applied as eyedrops. Intravitreal (IVT) injections are thus utilized to administer these therapies directly into the vitreous, positioned in front of the retina, ensuring optimal efficacy.
Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=259%20&type=requestsample
Intravitreal (IVT) Injectables Market Segmentation:
By Drug Class
- Anti-VEGF
- Antibiotics
- Corticosteroids
- Antifungals
- Antivirals
By Indication
- Diabetic Retinopathy
- Macular Degeneration
- Endophthalmitis
- Retinal Vein Occlusions
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in the Intravitreal (IVT) Injectables Market:
- Alcon Pharmaceuticals
- Novartis
- Regeneron Pharmaceuticals Inc.
- Allergan
- Alimera Sciences
- Bristol Myers Squibb
- Bausch And Lomb
- F. Hoffmann-La Roche
- Thrombogenics
- Valeant Pharmaceuticals International
Buy now the latest version of this report:
https://www.futurewiseresearch.com/checkout.aspx?ReportId=259&license=multi
**Objectives of this Study: **
- To provide a comprehensive analysis of the Intravitreal (IVT) Injectables Market By Drug Class, By Indication, By Distribution Channel and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
- You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com
